CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Fate Therapeutics, Inc. (FATE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Fate Therapeutics, Inc. (FATE)

Biological Products, (No Diagnostic Substances) · market cap $295M · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Fate Therapeutics (FATE) is a clinical-stage biotech with 181 employees and a ~$362M market cap, currently trading at ~$3.11. Its lead asset, ProTmune, is in Phase 2 for hematologic malignancies, and the company faces a critical near-term liquidity constraint with only ~$39.6M cash and roughly 3.9 months of runway.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
ProTmunePhase 2Hematologic Malignancies
FT839Phase 2ANCA-Associated Vasculitis (AAV)
FT819Phase 2Lupus Nephritis
Price & technical context
3-month
-56.7%
6-month
-51.9%
12-month
-1.0%
52-wk range
$0.98–$3.11
vs 50-day MA
-50.6%
vs 200-day MA
-49.1%
Realized vol
90.0%
Max drawdown
-78.5%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for FATE (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.